Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesEureka AI à l'intérieur
Services professionnels
Témoignages clients
Blog
Rapport mondial sur l'innovation
Glossaire
Newsroom
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport STT-MRAM reaches commercial inflection in 2026: embedded vs. standalone tradeoffs, endurance-retention physics, patent hotspots, and market projections to $7.9B.
Updated on April 13, 2026 | Written by PatSnap Team A novelty search in patent law is a structured investigation …
Continue reading "What Is a Patent Novelty Search? AI Changes 2026"
Updated on April 13, 2026 | Written by PatSnap Team AI drug discovery depends on three distinct categories of data …
Continue reading "AI Drug Discovery Data: Patents, Biosequences & Structures"
Updated on April 13, 2026 | Written by PatSnap Team Patent claim parsing is the process of decomposing a patent …
Continue reading "How Patent Claim Parsing Works in AI IP Analysis"
Updated on April 13, 2026 | Written by PatSnap Team Discover which patent API includes biosequence and chemical structure data …
Continue reading "Patent API with Biosequence & Chemical Data 2026"
Updated on April 10, 2026 | Written by PatSnap Team Building an AI-powered freedom-to-operate (FTO) analysis tool requires more than …
Continue reading "Best Patent Data API for FTO Analysis 2026"
Updated on April 10, 2026 | Written by PatSnap Team If you’re building AI workflows in Cursor or Claude Desktop …
Continue reading "MCP Server for Patent Data: Best Tools 2026"
Article | Rapport How RORγt inverse agonists (VTP-43742, ABBV-157) differ mechanistically from IL-23p19 antibodies in Th17 suppression — clinical tolerability, tissue pharmacodynamics, and patent evidence.
Article | Rapport How do oral small molecule IL-17A inhibitors compare to Bimekizumab? Explore the mechanistic rationale, patent landscape, and oral bioavailability solutions.
Article | Rapport Explore Applied Materials' semiconductor deposition, etch, and materials engineering technology roadmap from 2010 to 2026—key innovations, process trends, and future outlook.
Article | Rapport Silicon photonics vs. InP vs. thin-film LiNbO₃: a 2026 PIC technology landscape covering data center demand, performance benchmarks, and market growth.
Article | Rapport How satralizumab, sarilumab, and siltuximab differ in IL-6 pathway blockade, CNS penetrance, and patent-disclosed antibody engineering for half-life extension.
Article | Rapport MBCFET vs nanosheet vs forksheet: compare GAA transistor architectures, process integration challenges, and the 2026 competitive landscape from Samsung to TSMC.
Article | Rapport Telitacicept vs. Belimumab in IgA nephropathy and SLE: mechanistic rationale for dual APRIL/BAFF blockade and clinical evidence on IgA levels, proteinuria, and B-cell dynamics.
Article | Rapport How allosteric TYK2 pseudokinase inhibition achieves IL-12/IL-23/IFN-α selectivity while avoiding JAK1/2/3 hematopoietic and thromboembolic risks — clinical evidence in psoriasis and SLE.